Fate of endothelial cells after intrastromal implantation of Descemet's membrane-endothelial cell tissue.


Journal

Cell and tissue banking
ISSN: 1573-6814
Titre abrégé: Cell Tissue Bank
Pays: Netherlands
ID NLM: 100965121

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 19 03 2020
accepted: 25 05 2020
revised: 21 05 2020
pubmed: 4 6 2020
medline: 4 6 2021
entrez: 4 6 2020
Statut: ppublish

Résumé

In non-Descemet Stripping Automated Endothelial Keratoplasty (nDSAEK), the host DM and endothelium are not removed surgically before the introduction of the posterior lamellar graft; the result is that the patient has both the healthy donor endothelium and the diseased or residual host endothelium. Conversely, DSAEK tissues, that are inserted with inverted polarity (upside down), do not survive and the graft fails. While the mechanism of endothelial cell transplantation is clear, the fate of the endothelial cells retained between two stromal interfaces and their physiological role, if any, is not well understood. The aim of our study was therefore to evaluate the viability of a healthy endothelial-Descemet's membrane (EDM) graft after the insertion into a stromal pocket of a recipient donor cornea. Research corneas (n = 52) were divided into three groups: Group A, where an EDM (obtained from another cornea) with good endothelium was inserted in a stromal pocket endothelium side down; Group B, consisting of control corneas with a stromal pocket but without EDM insertion; and Group C, pre-stripped membranes resting on their stroma (not in a stromal pocket). The tissues were preserved in tissue culture medium for 21 days at 31 °C. Parameters including viability of endothelial cells, expression of tight junctions (ZO-1) and thickness were evaluated. After 21 days, all the membranes inserted within the stromal pocket of Group A survived, although an average endothelial cell loss of 30.1% (± 18.10) and a mortality of 10.2% (± 22.86) were recorded. Qualitative analysis using triple staining with Hoechst, ethidium homodimer and calcein AM confirmed the mortality. ZO-1 was expressed where the cells were present, showing good integrity of tight junctions. Group C showed an average endothelial cell loss of 1.9% (± 3.38), a mortality of 0.02% (± 0.07) and a higher expression of ZO-1. An EDM graft with endothelium facing downwards can survive in a stromal pocket for at least 3 weeks, with an overall cell mortality of 30%. Further studies are needed to evaluate the possible outcomes of the insertion of a healthy intrastromal EDMs with reverse polarity and in edematous corneas.

Identifiants

pubmed: 32488653
doi: 10.1007/s10561-020-09840-5
pii: 10.1007/s10561-020-09840-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

535-545

Auteurs

Pietro Rosetta (P)

Humanitas San Pio X Hospital, Milan, Italy.

Alessandro Ruzza (A)

Fondazione Banca degli Occhi del Veneto, Via Paccagnella 11, Venice, Italy.

Mohit Parekh (M)

Fondazione Banca degli Occhi del Veneto, Via Paccagnella 11, Venice, Italy.
UCL Institute Of Ophthalmology, London, UK.

Paola Gallon (P)

Fondazione Banca degli Occhi del Veneto, Via Paccagnella 11, Venice, Italy.

Riccardo Vinciguerra (R)

Humanitas San Pio X Hospital, Milan, Italy.

Stefano Ferrari (S)

Fondazione Banca degli Occhi del Veneto, Via Paccagnella 11, Venice, Italy. stefano.ferrari@fbov.it.

Harminder S Dua (HS)

Larry A Donoso Laboratory for Eye Research, Academic Section of Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham University Hospitals, NHS Trust, Nottingham, England, UK.

Diego Ponzin (D)

Fondazione Banca degli Occhi del Veneto, Via Paccagnella 11, Venice, Italy.

Paolo Vinciguerra (P)

Humanitas Clinical and Research Center - IRCCS, via Manzoni 56, 20089, Rozzano, MI, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH